Blood-Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study.
Kuitunen HK, Rönkä ALK, Sonkajärvi EM, Isokangas JM, Pyörälä M, Palosaari KAA, Jokimäki AS, Partanen AE, Littow HJ, Vakkala MA, Jantunen EJ, Huttunen ME, Marin KJ, Aromaa-Häyhä AMK, Auvinen PK, Selander T, Puhakka IK, Kuittinen OM.
Kuitunen HK, et al. Among authors: ronka alk.
Cancers (Basel). 2023 Feb 20;15(4):1341. doi: 10.3390/cancers15041341.
Cancers (Basel). 2023.
PMID: 36831682
Free PMC article.